Literature DB >> 22926096

Thyroid gland: vandetanib for thyroid cancer.

Iley Ozerlat.   

Abstract

Entities:  

Year:  2012        PMID： 22926096     DOI： 10.1038/nrendo.2012.157

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Authors:  Sophie Leboulleux; Lars Bastholt; Thomas Krause; Christelle de la Fouchardiere; Jan Tennvall; Ahmad Awada; José Manuel Gómez; Françoise Bonichon; Laurence Leenhardt; Christine Soufflet; Muriel Licour; Martin J Schlumberger
Journal:  Lancet Oncol       Date:  2012-08-14       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.